Date | Title | Description | |
---|---|---|---|
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
27 Feb 2024 | Annual Financial Reports and Audit Reports | The Company submits the 2023 Annual Financial Report | Download |
27 Feb 2024 | Annual Corporate Governance Report | ROVI releases the 2023 Annual Corporate Governance Report | Download |
27 Feb 2024 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2023 annual report regarding remuneration of the members of the Board of Directors. | Download |
23 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 16 February and 22 February 2024 | Download |
16 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 9 February and 15 February 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Nov 2012 | Composición Consejo de Administración | Download | |
18 Sep 2012 | Otros sobre negocio y situación financiera | Download | |
26 Jul 2012 | Información sobre resultados (2) | Download | |
26 Jul 2012 | Información sobre resultados | Download | |
26 Jul 2012 | Información financiera intermedia | Download |